A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis.
Gavin GiovannoniShona Helen LangRobert WolffSteven DuffyRobert HydeElizabeth KinterCraig WakefordMaria Pia SormaniJos M P KleijnenPublished in: Neurology and therapy (2020)
Meta-analyses confirmed the benefit of all DMTs in terms of relapse rate compared with placebo with a comparable rate of SAEs for the DMTs that could be included in the network. The rigor and transparency of reporting in this study provide a benchmark for comparisons with future new agents.